

28 April 2021

## Charnwood Molecular unveils plans to quadruple capacity

[Synova](#) portfolio company, [Charnwood Molecular](#), a leading UK-based outsourced drug discovery CRO servicing the global pharmaceutical and biotechnology market, has announced a milestone investment in its ambitious growth strategy. The company will become the sole occupier of a substantial 3-storey, state-of-the-art laboratory facility later this year at [Charnwood Campus](#), Loughborough. The facility will **increase Charnwood Molecular's physical capacity four-fold** with flexible lab space supporting the company's projected headcount growth and capability expansions. Charnwood Campus is a Science, Innovation and Technology Park set in 70 acres of landscaped grounds in Loughborough.

Charnwood Molecular has seen significant expansion of its global client base in recent years. This latest physical expansion of the company will support its growth plan across a wide range of contract research services: from medicinal chemistry, chemical development and early process research through to developing a suite of complementary services in order to provide a holistic pre-clinical discovery portfolio to its international client base.

[Steve Allin](#), CEO of Charnwood Molecular, commented: *"The truly world-class facilities at Charnwood Campus provide us with a key piece in our strategic plan to become the provider of choice for integrated drug discovery and development services within the global life sciences sector. The new laboratories will provide substantial capacity for future growth and expansion of our medicinal chemistry and process research teams, along with the addition of related drug discovery service lines."*

ENDS

**NOTES:**

1. **Synova** is recognised across the industry as one of Europe's most innovative growth investors, investing in companies typically valued between £30m and £150m. We invest across a handful of core sectors, including **Technology**, **Financial Services**, **Business Services**, and **Health & Education**, where we have deep investment and operational expertise
2. Synova has generated industry-leading returns, which has been reflected in being awarded [\*UK Private Equity House of the Year\*](#) four times in the past seven years. We are currently investing our fourth generation fund, raised in 2019
3. Synova has completed a number of new investments and successful exits across the **Health** sector with the sales of **4Ways** to ECI Partners (6.0x invested capital) and **Kinapse** to HgCapital (16.1x invested capital); and investments in **Charnwood Molecular** (drug discovery services), **PreventX** (online-led sexual health testing and diagnostics), **Clyde Munro** (Scottish dental consolidation platform) and **Oakland Care** (premium residential elderly care)

**CONTACT:**

Zac Tsai, Partner, Tel: +44 (0)20 3475 7658

Tim Ashlin, Partner, Tel: +44 (0)20 3475 7668